HSA
MDGL icon

Hussman Strategic Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Hussman Strategic Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
+2,100
New +$1.08M 0.26% 173

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hussman Strategic Advisors's MDGL Position: Q2 2026 in Review

Hussman Strategic Advisors opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 2,100 shares worth $1.13M. The stake represents 0.26% of the portfolio and ranks #173 among its holdings.

413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Hussman Strategic Advisors held 2,100 shares of Madrigal Pharmaceuticals worth $1.13M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Hussman Strategic Advisors position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.26% of Hussman Strategic Advisors's portfolio in Q2 2026, its #173 holding.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.